Alcobra Ltd.
(NASDAQ : ADHD)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Loading ADHD News...
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
SHPGShire PLC Sponsored ADR
-0.07%165.929.9%$682.37m
VRXValeant Pharmaceuticals International, Inc.
-5.82%19.097.1%$555.49m
PRGOPerrigo Co. Plc
-2.19%89.024.0%$241.27m
ENDPEndo International Plc
-5.99%13.964.1%$123.51m
JAZZJazz Pharmaceuticals Plc
-3.58%132.972.7%$118.49m
MNKMallinckrodt Plc
-2.70%54.4611.7%$86.46m
ICPTIntercept Pharmaceuticals, Inc.
-7.38%132.3713.8%$82.61m
RLYPRelypsa, Inc.
-7.92%16.0533.0%$63.59m
HZNPHorizon Pharma plc
-5.79%15.319.7%$60.74m
UTHRUnited Therapeutics Corporation
-2.63%99.4219.5%$59.73m
MDCOMedicines Company
0.93%33.5719.6%$47.68m
CTLTCatalent Inc
-6.19%21.384.1%$43.93m
GWPHGW Pharmaceuticals PLC Sponsored ADR
8.15%90.1012.2%$40.78m
ICLRICON Plc
-1.01%66.943.3%$35.21m
ALRAlere Inc.
-1.80%40.854.7%$29.81m

Company Profile

Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel.